Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

Texas MPN Workshop 2020 | Targeted therapies in combination with ruxolitinib

Lucia Masarova • 21 Aug 2020

Texas MPN Workshop 2020

Myelofibrosis Azacitidine Buparlisib CPI-0610 Navitoclax Ruxolitinib

MANIFEST

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the use of novel targeted therapies in combination with ruxolitinib, a JAK inhibitor. These include results of the MANIFEST study (NCT02158858) combining a BET inhibtor with ruxolitinib in myelofibrosis, azaciditine with ruxolitinib, as well as studies evaluating the BCL-2 inhibitor, venetoclax in combination with JAK inhibition. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

What's on the horizon for the treatment of MPNs?

Lucia Masarova • 9 Dec 2023

Splicing mutations in post-ET/post-PV myelofibrosis

Lucia Masarova • 9 Dec 2023

Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1

Lucia Masarova • 9 Dec 2023

Cladribine-based chemotherapy for patients with secondary AML arising after MPNs

Lucia Masarova • 9 Dec 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023